FluGen, Startup Developing Universal Flu Vaccine, Raises $5.5M
Summary
FluGen, Startup Developing Universal Flu Vaccine, Raises $5.5M Xconomy Wisconsin — FluGen, an early-stage company developing vaccine candidates designed to protect against multiple types of influenza, has raised $5.5 million in debt financing.In July 2016, FluGen initiated a Phase 1a clinical trial of its experimental universal influenza vaccine, known as RedeeFlu.The purpose of the study is to assess the safety of the vaccine, and to evaluate antibody and T-cell responses in participating patients.Paul Radspinner, co-founder and CEO of FluGen, said in April that 96 patients were dosed with the RedeeFlu vaccine as part of the trial, and the company expected to have data on them later in the year.Each year, groups such as the World Health Organization and Centers for Disease Control and Prevention forecast what they believe will be the predominant strains for the coming flu season.